NASDAQ:GOSS - Gossamer Bio Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $19.64 +0.34 (+1.76 %) (As of 02/19/2019 04:00 PM ET)Previous Close$19.30Today's Range$19.14 - $20.0052-Week Range$16.00 - $19.77Volume377,694 shsAverage Volume854,160 shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California. Receive GOSS News and Ratings via Email Sign-up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GOSS Previous Symbol CUSIPN/A Webwww.gossamerbio.com Phone858-922-0718Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares60,402,000Market Cap$1.19 billion OptionableNot Optionable Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions What is Gossamer Bio's stock symbol? Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS." Has Gossamer Bio been receiving favorable news coverage? Media coverage about GOSS stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gossamer Bio earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. Who are some of Gossamer Bio's key competitors? Some companies that are related to Gossamer Bio include ORION OYJ/ADR (ORINY), Medidata Solutions (MDSO), Guardant Health (GH), GW Pharmaceuticals PLC- (GWPH), Haemonetics (HAE), Amedisys (AMED), Healthscope (HSO), Integra Lifesciences (IART), BTG (BTGGF), Taro Pharmaceutical Industries (TARO), TESARO (TSRO), Amneal Pharmaceuticals (AMRX), argenx (ARGX), Wright Medical Group (WMGI) and Horizon Pharma (HZNP). Who are Gossamer Bio's key executives? Gossamer Bio's management team includes the folowing people: Mr. Faheem Hasnain, Co-Founder & Exec. Chairman (Age 61)Dr. Sheila K. Gujrathi M.D., Co-Founder, Pres, CEO & Director (Age 49)Mr. Bryan Giraudo, Chief Financial Officer (Age 44)Mr. Christian Waage, Exec. VP, Gen. Counsel & Sec. (Age 52)Dr. Jakob Dupont, Chief Medical Officer (Age 54) When did Gossamer Bio IPO? (GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO. When does Gossamer Bio's quiet period expire? Gossamer Bio's quiet period expires on Wednesday, March 20th. Gossamer Bio had issued 17,250,000 shares in its public offering on February 8th. The total size of the offering was $276,000,000 based on an initial share price of $16.00. During Gossamer Bio's quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company. How do I buy shares of Gossamer Bio? Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Gossamer Bio's stock price today? One share of GOSS stock can currently be purchased for approximately $19.64. How big of a company is Gossamer Bio? Gossamer Bio has a market capitalization of $1.19 billion. What is Gossamer Bio's official website? The official website for Gossamer Bio is http://www.gossamerbio.com. How can I contact Gossamer Bio? Gossamer Bio's mailing address is 3013 SCIENCE PARK SUITE 200, SAN DIEGO CA, 92121. The company can be reached via phone at 858-922-0718. MarketBeat Community Rating for Gossamer Bio (NASDAQ GOSS)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 3 (Vote Outperform)Underperform Votes: 4 (Vote Underperform)Total Votes: 7MarketBeat's community ratings are surveys of what our community members think about Gossamer Bio and other stocks. Vote "Outperform" if you believe GOSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GOSS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: How Do You Calculate Return on Investment (ROI)?